arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Citius Pharmaceuticals, Inc.

CTXR
$0.57 ▼ -0.03 (-5.09%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
63 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Citius Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $14.9M
Dividend Yield —
Revenue Growth —
Op. Margin None
ROIC -17.5% ↗
FCF / Share $-0.33 ↘
Trailing P/E —
Price / Book 0.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.49M
↓ -10.4% —
Net Income Profit after all expenses
$-9.39M
↑ +8.6% —
FCF / Share Free cash flow per share
$-0.33
↓ -470.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
15
Financial Health ↑
5
Cash Quality ↓
47

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 63 quarters